INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Corporate insider
FR

Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRSCIK 0001898490

EDGAR filingsOpen in network
Disclosed transactions14
Buys / sells0 / 9
Max Insider Score15
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
2
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
124.4K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Theravance Biopharma, Inc.SVP, COMM & MEDICAL AFFAIRS · Nov 24, 2025
2
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D
—
150.0K sh
Sep 23, 2026
Sep 24, 2026
traded Sep 23, 2026
+1d
SEC FORM 4

Evidence

2
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
89.1K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

1
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$57K
3,329 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

1
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$57K
3,328 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

1
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$113K
6,657 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

5
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Tax withholding
F$96K
5,667 sh
Aug 20, 2026Aug 24, 2026
traded Aug 20, 2026
+4dSEC FORM 4

Evidence

4
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$108K
7,766 sh
Mar 16, 2026Mar 18, 2026
traded Mar 16, 2026
+2dSEC FORM 4

Evidence

4
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$108K
7,767 sh
Mar 16, 2026Mar 18, 2026
traded Mar 16, 2026
+2dSEC FORM 4

Evidence

8
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$217K
15.5K sh
Mar 16, 2026Mar 18, 2026
traded Mar 16, 2026
+2dSEC FORM 4

Evidence

8
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$146K
7,767 sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

8
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$146K
7,766 sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

15
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Open-market sale · 10b5-1 plan
SELL$291K
15.5K sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

12
FR
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
TBPHTheravance Biopharma, Inc.
Tax withholding
F$162K
9,060 sh
Nov 20, 2025Nov 24, 2025
traded Nov 20, 2025
+4dSEC FORM 4

Evidence